<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00822185</url>
  </required_header>
  <id_info>
    <org_study_id>NN1731-3604</org_study_id>
    <secondary_id>JapicCTI-090681</secondary_id>
    <nct_id>NCT00822185</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of NN1731 in Healthy Volunteers</brief_title>
  <official_title>A Single-centre, Randomised, Placebo-controlled, Double-blind, Single-dose, Dose-escalation Trial to Assess the Safety, Tolerability and Pharmacokinetics of Ascending Intravenous Doses of an Activated Recombinant FVII Analogue (NN1731) in Healthy Japanese Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Japan. The aim of this trial is to assess the safety and
      tolerability of activated recombinant human coagulation factor VII analogue (NN1731,
      vatreptacog alfa (activated)) in healthy Japanese male subjects. In addition, the
      pharmacokinetics of NN1731 will be examined
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (Physical Examination, Vital Signs, ECG, Haematology, Biochemistry, Urinalysis, Coagulation Factors, Coagulation-related Parameters, Injection Site Tolerability and Adverse Events (AE))</measure>
    <time_frame>between dosing and 2-3 weeks after dosing</time_frame>
    <description>Any safety issue was reported as AE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjects With Anti-Vatreptacog Alfa Antibody</measure>
    <time_frame>between dosing, 2-3 weeks after dosing, and 11-13 weeks after dosing</time_frame>
    <description>Post-dosing samples from subjects were evaluated for the presence of Anti-Vatreptacog alfa antibody</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vatreptacog Alfa Clot Activity: Area Under the FVIIa Activity-time Curve From Time 0 and up Until the Last Quantifiable Activity (AUC0-t)</measure>
    <time_frame>during 1-2 days after drug administration</time_frame>
    <description>AUC0-t was computed using the linear trapezoid rule. Plasma FVIIa clot activity at time 0 was calculated by log linear interpolation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vatreptacog Alfa Clot Activity: Area Under the FVIIa Activity-time Curve From Time 0 to 24 h (AUC0-24)</measure>
    <time_frame>during 1-2 days after drug administration</time_frame>
    <description>Blood samples were collected at following time points: -30 min, -20 min, -10 min, 5 min, 10 min, 20 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 8h, 12h and 24h to calculate area under the curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vatreptacog Alfa Clot Activity: Area Under the FVIIa Activity-time Curve From Time 0 h to Infinity (AUC 0-inf)</measure>
    <time_frame>during 1-2 days after drug administration</time_frame>
    <description>AUC0-inf = AUC0-t + (Ct / λz), Where Ct is the last quantifiable activity and t the time of Ct.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vatreptacog Alfa Clot Activity: Maximum FVIIa Activity (Cmax)</measure>
    <time_frame>during 1-2 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vatreptacog Alfa Clot Activity: FVIIa Activity Measured 5 Min After Administration of NN1731 (C5min)</measure>
    <time_frame>during 1-2 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vatreptacog Alfa Clot Activity: Back Extrapolated Estimate of the Initial FVIIa Activity (C0)</measure>
    <time_frame>during 1-2 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vatreptacog Alfa Clot Activity- Terminal Slope (λz)</measure>
    <time_frame>during 1-2 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vatreptacog Alfa Clot Activity: Terminal Half-life (t1/2)</measure>
    <time_frame>during 1-2 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vatreptacog Alfa Clot Activity- Total Clearance (CL)</measure>
    <time_frame>during 1-2 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vatreptacog Alfa Clot Activity- Apparent Volume of Distribution at Steady State (Vss)</measure>
    <time_frame>during 1-2 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vatreptacog Alfa Clot Activity- Initial Volume of Distribution (VD)</measure>
    <time_frame>during 1-2 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vatreptacog Alfa Clot Activity- Mean Residence Time (MRT)</measure>
    <time_frame>during 1-2 days after drug administration</time_frame>
    <description>Mean residence time of the unchanged drug in the systemic circulation</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Congenital Bleeding Disorder</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>vatreptacog alfa, 5 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>vatreptacog alfa, 10 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>vatreptacog alfa, 20 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>vatreptacog alfa, 30 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vatreptacog alfa (activated)</intervention_name>
    <description>One single dose is injected i.v. over 2 minutes to 6 subjects, 5 mcg/kg</description>
    <arm_group_label>vatreptacog alfa, 5 mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vatreptacog alfa (activated)</intervention_name>
    <description>One single dose is injected i.v. over 2 minutes to 6 subjects, 10 mcg/kg</description>
    <arm_group_label>vatreptacog alfa, 10 mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vatreptacog alfa (activated)</intervention_name>
    <description>One single dose is injected i.v. over 2 minutes to 6 subjects, 20 mcg/kg</description>
    <arm_group_label>vatreptacog alfa, 20 mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vatreptacog alfa (activated)</intervention_name>
    <description>One single dose is injected i.v. over 2 minutes to 6 subjects, 30 mcg/kg</description>
    <arm_group_label>vatreptacog alfa, 30 mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 5 mcg/kg</description>
    <arm_group_label>vatreptacog alfa, 5 mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 10 mcg/kg</description>
    <arm_group_label>vatreptacog alfa, 10 mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 20 mcg/kg</description>
    <arm_group_label>vatreptacog alfa, 20 mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 30 mcg/kg</description>
    <arm_group_label>vatreptacog alfa, 30 mcg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese male subjects, who are considered to be generally healthy based on assessment
             of medical history, physical examination and clinical laboratory data at screening, as
             judged by the Investigator or Sub-investigator

          -  Body Mass Index (BMI) between 18.0 and 27.0 kg/m^2 (inclusive)

        Exclusion Criteria:

          -  Any clinical laboratory values deviated from the reference range at the laboratory
             (except for cases within physiological change) or any abnormal electrocardiogram (ECG)
             findings at the screening, as judged by the Investigator or Sub-investigator

          -  Presence or history of cancer or any clinically significant cardiac, respiratory,
             metabolic, renal, hepatic, gastrointestinal, endocrinological, dermatological,
             venereal, haematological, neurological, or psychiatric diseases or disorders

          -  Evidence of clinically relevant pathology or a potential thromboembolic risk as judged
             by the Investigator or Sub-investigator

          -  Presence or history of atherosclerosis, arteriosclerosis or thromboembolic events

          -  Any past history of migraine

          -  Overt bleeding, including from the gastrointestinal tract
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <zip>130-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2009</study_first_submitted>
  <study_first_submitted_qc>January 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2009</study_first_posted>
  <results_first_submitted>September 27, 2013</results_first_submitted>
  <results_first_submitted_qc>September 22, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 23, 2014</results_first_posted>
  <last_update_submitted>December 12, 2014</last_update_submitted>
  <last_update_submitted_qc>December 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This trial was conducted at a single site in Japan.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Vatreptacog Alfa 5 mcg/kg</title>
          <description>A single dose of Vatreptacog alfa 5 mcg/kg bodyweight was administered intravenously</description>
        </group>
        <group group_id="P2">
          <title>Vatreptacog Alfa 10 mcg/kg</title>
          <description>A single dose of Vatreptacog alfa 10 mcg/kg bodyweight was administered intravenously</description>
        </group>
        <group group_id="P3">
          <title>Vatreptacog Alfa 20 mcg/kg</title>
          <description>A single dose of Vatreptacog alfa 20 mcg/kg bodyweight was administered intravenously</description>
        </group>
        <group group_id="P4">
          <title>Vatreptacog Alfa 30 mcg/kg</title>
          <description>A single dose of Vatreptacog alfa 30 mcg/kg bodyweight was administered intravenously</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>A single dose of placebo was administered intravenously</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vatreptacog Alfa 5 mcg/kg</title>
          <description>A single dose of Vatreptacog alfa 5 mcg/kg bodyweight was administered intravenously</description>
        </group>
        <group group_id="B2">
          <title>Vatreptacog Alfa 10 mcg/kg</title>
          <description>A single dose of Vatreptacog alfa 10 mcg/kg bodyweight was administered intravenously</description>
        </group>
        <group group_id="B3">
          <title>Vatreptacog Alfa 20 mcg/kg</title>
          <description>A single dose of Vatreptacog alfa 20 mcg/kg bodyweight was administered intravenously</description>
        </group>
        <group group_id="B4">
          <title>Vatreptacog Alfa 30 mcg/kg</title>
          <description>A single dose of Vatreptacog alfa 30 mcg/kg bodyweight was administered intravenously</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>A single dose of placebo was administered intravenously</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.8" spread="6.5"/>
                    <measurement group_id="B2" value="23.3" spread="3.4"/>
                    <measurement group_id="B3" value="26.5" spread="3.5"/>
                    <measurement group_id="B4" value="26.3" spread="5.1"/>
                    <measurement group_id="B5" value="26.5" spread="7.7"/>
                    <measurement group_id="B6" value="26.3" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety (Physical Examination, Vital Signs, ECG, Haematology, Biochemistry, Urinalysis, Coagulation Factors, Coagulation-related Parameters, Injection Site Tolerability and Adverse Events (AE))</title>
        <description>Any safety issue was reported as AE</description>
        <time_frame>between dosing and 2-3 weeks after dosing</time_frame>
        <population>Safety analysis set included all the randomised subjects who received at least one dose of the trial product.</population>
        <group_list>
          <group group_id="O1">
            <title>Vatreptacog Alfa 5 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 5 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O2">
            <title>Vatreptacog Alfa 10 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 10 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O3">
            <title>Vatreptacog Alfa 20 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 20 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O4">
            <title>Vatreptacog Alfa 30 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 30 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>A single dose of placebo was administered intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Safety (Physical Examination, Vital Signs, ECG, Haematology, Biochemistry, Urinalysis, Coagulation Factors, Coagulation-related Parameters, Injection Site Tolerability and Adverse Events (AE))</title>
          <description>Any safety issue was reported as AE</description>
          <population>Safety analysis set included all the randomised subjects who received at least one dose of the trial product.</population>
          <units>number of events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subjects With Anti-Vatreptacog Alfa Antibody</title>
        <description>Post-dosing samples from subjects were evaluated for the presence of Anti-Vatreptacog alfa antibody</description>
        <time_frame>between dosing, 2-3 weeks after dosing, and 11-13 weeks after dosing</time_frame>
        <population>Safety analysis set included all the randomised subjects who received at least one dose of the trial product.</population>
        <group_list>
          <group group_id="O1">
            <title>Vatreptacog Alfa 5 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 5 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O2">
            <title>Vatreptacog Alfa 10 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 10 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O3">
            <title>Vatreptacog Alfa 20 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 20 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O4">
            <title>Vatreptacog Alfa 30 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 30 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>A single dose of placebo was administered intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Anti-Vatreptacog Alfa Antibody</title>
          <description>Post-dosing samples from subjects were evaluated for the presence of Anti-Vatreptacog alfa antibody</description>
          <population>Safety analysis set included all the randomised subjects who received at least one dose of the trial product.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vatreptacog Alfa Clot Activity: Area Under the FVIIa Activity-time Curve From Time 0 and up Until the Last Quantifiable Activity (AUC0-t)</title>
        <description>AUC0-t was computed using the linear trapezoid rule. Plasma FVIIa clot activity at time 0 was calculated by log linear interpolation.</description>
        <time_frame>during 1-2 days after drug administration</time_frame>
        <population>PK analysis set included all the subjects not violating the protocol in a manner that was judged to affect PK endpoint evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Vatreptacog Alfa 5 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 5 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O2">
            <title>Vatreptacog Alfa 10 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 10 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O3">
            <title>Vatreptacog Alfa 20 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 20 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O4">
            <title>Vatreptacog Alfa 30 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 30 mcg/kg bodyweight was administered intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Vatreptacog Alfa Clot Activity: Area Under the FVIIa Activity-time Curve From Time 0 and up Until the Last Quantifiable Activity (AUC0-t)</title>
          <description>AUC0-t was computed using the linear trapezoid rule. Plasma FVIIa clot activity at time 0 was calculated by log linear interpolation.</description>
          <population>PK analysis set included all the subjects not violating the protocol in a manner that was judged to affect PK endpoint evaluation.</population>
          <units>(IU*h)/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.875" spread="10.7"/>
                    <measurement group_id="O2" value="13.845" spread="15.0"/>
                    <measurement group_id="O3" value="30.268" spread="7.5"/>
                    <measurement group_id="O4" value="46.986" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vatreptacog Alfa Clot Activity: Area Under the FVIIa Activity-time Curve From Time 0 to 24 h (AUC0-24)</title>
        <description>Blood samples were collected at following time points: -30 min, -20 min, -10 min, 5 min, 10 min, 20 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 8h, 12h and 24h to calculate area under the curve.</description>
        <time_frame>during 1-2 days after drug administration</time_frame>
        <population>PK analysis set included all the subjects not violating the protocol in a manner that was judged to affect PK endpoint evaluation. One (1) subject did not contribute to PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Vatreptacog Alfa 5 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 5 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O2">
            <title>Vatreptacog Alfa 10 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 10 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O3">
            <title>Vatreptacog Alfa 20 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 20 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O4">
            <title>Vatreptacog Alfa 30 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 30 mcg/kg bodyweight was administered intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Vatreptacog Alfa Clot Activity: Area Under the FVIIa Activity-time Curve From Time 0 to 24 h (AUC0-24)</title>
          <description>Blood samples were collected at following time points: -30 min, -20 min, -10 min, 5 min, 10 min, 20 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 8h, 12h and 24h to calculate area under the curve.</description>
          <population>PK analysis set included all the subjects not violating the protocol in a manner that was judged to affect PK endpoint evaluation. One (1) subject did not contribute to PK evaluation.</population>
          <units>(IU*h)/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.970" spread="11.8"/>
                    <measurement group_id="O2" value="13.143" spread="8.1"/>
                    <measurement group_id="O3" value="30.310" spread="7.5"/>
                    <measurement group_id="O4" value="47.021" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vatreptacog Alfa Clot Activity: Area Under the FVIIa Activity-time Curve From Time 0 h to Infinity (AUC 0-inf)</title>
        <description>AUC0-inf = AUC0-t + (Ct / λz), Where Ct is the last quantifiable activity and t the time of Ct.</description>
        <time_frame>during 1-2 days after drug administration</time_frame>
        <population>PK analysis set included all the subjects not violating the protocol in a manner that was judged to affect PK endpoint evaluation. One (1) subject did not contribute to PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Vatreptacog Alfa 5 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 5 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O2">
            <title>Vatreptacog Alfa 10 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 10 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O3">
            <title>Vatreptacog Alfa 20 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 20 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O4">
            <title>Vatreptacog Alfa 30 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 30 mcg/kg bodyweight was administered intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Vatreptacog Alfa Clot Activity: Area Under the FVIIa Activity-time Curve From Time 0 h to Infinity (AUC 0-inf)</title>
          <description>AUC0-inf = AUC0-t + (Ct / λz), Where Ct is the last quantifiable activity and t the time of Ct.</description>
          <population>PK analysis set included all the subjects not violating the protocol in a manner that was judged to affect PK endpoint evaluation. One (1) subject did not contribute to PK evaluation.</population>
          <units>(IU*h)/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.128" spread="14.7"/>
                    <measurement group_id="O2" value="13.195" spread="8.1"/>
                    <measurement group_id="O3" value="30.351" spread="7.7"/>
                    <measurement group_id="O4" value="47.060" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vatreptacog Alfa Clot Activity: Maximum FVIIa Activity (Cmax)</title>
        <time_frame>during 1-2 days after drug administration</time_frame>
        <population>PK analysis set included all the subjects not violating the protocol in a manner that was judged to affect PK endpoint evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Vatreptacog Alfa 5 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 5 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O2">
            <title>Vatreptacog Alfa 10 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 10 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O3">
            <title>Vatreptacog Alfa 20 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 20 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O4">
            <title>Vatreptacog Alfa 30 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 30 mcg/kg bodyweight was administered intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Vatreptacog Alfa Clot Activity: Maximum FVIIa Activity (Cmax)</title>
          <population>PK analysis set included all the subjects not violating the protocol in a manner that was judged to affect PK endpoint evaluation.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.767" spread="10.4"/>
                    <measurement group_id="O2" value="27.569" spread="13.9"/>
                    <measurement group_id="O3" value="55.732" spread="5.9"/>
                    <measurement group_id="O4" value="86.974" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vatreptacog Alfa Clot Activity: FVIIa Activity Measured 5 Min After Administration of NN1731 (C5min)</title>
        <time_frame>during 1-2 days after drug administration</time_frame>
        <population>PK analysis set included all the subjects not violating the protocol in a manner that was judged to affect PK endpoint evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Vatreptacog Alfa 5 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 5 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O2">
            <title>Vatreptacog Alfa 10 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 10 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O3">
            <title>Vatreptacog Alfa 20 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 20 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O4">
            <title>Vatreptacog Alfa 30 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 30 mcg/kg bodyweight was administered intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Vatreptacog Alfa Clot Activity: FVIIa Activity Measured 5 Min After Administration of NN1731 (C5min)</title>
          <population>PK analysis set included all the subjects not violating the protocol in a manner that was judged to affect PK endpoint evaluation.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.767" spread="10.4"/>
                    <measurement group_id="O2" value="27.569" spread="13.9"/>
                    <measurement group_id="O3" value="55.732" spread="5.9"/>
                    <measurement group_id="O4" value="86.974" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vatreptacog Alfa Clot Activity: Back Extrapolated Estimate of the Initial FVIIa Activity (C0)</title>
        <time_frame>during 1-2 days after drug administration</time_frame>
        <population>PK analysis set included all the subjects not violating the protocol in a manner that was judged to affect PK endpoint evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Vatreptacog Alfa 5 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 5 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O2">
            <title>Vatreptacog Alfa 10 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 10 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O3">
            <title>Vatreptacog Alfa 20 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 20 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O4">
            <title>Vatreptacog Alfa 30 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 30 mcg/kg bodyweight was administered intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Vatreptacog Alfa Clot Activity: Back Extrapolated Estimate of the Initial FVIIa Activity (C0)</title>
          <population>PK analysis set included all the subjects not violating the protocol in a manner that was judged to affect PK endpoint evaluation.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.802" spread="8.4"/>
                    <measurement group_id="O2" value="34.497" spread="14.2"/>
                    <measurement group_id="O3" value="69.474" spread="7.3"/>
                    <measurement group_id="O4" value="106.916" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vatreptacog Alfa Clot Activity- Terminal Slope (λz)</title>
        <time_frame>during 1-2 days after drug administration</time_frame>
        <population>PK analysis set included all the subjects not violating the protocol in a manner that was judged to affect PK endpoint evaluation. One (1) subject did not contribute to PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Vatreptacog Alfa 5 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 5 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O2">
            <title>Vatreptacog Alfa 10 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 10 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O3">
            <title>Vatreptacog Alfa 20 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 20 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O4">
            <title>Vatreptacog Alfa 30 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 30 mcg/kg bodyweight was administered intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Vatreptacog Alfa Clot Activity- Terminal Slope (λz)</title>
          <population>PK analysis set included all the subjects not violating the protocol in a manner that was judged to affect PK endpoint evaluation. One (1) subject did not contribute to PK evaluation.</population>
          <units>1/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="59.0"/>
                    <measurement group_id="O2" value="0.14" spread="32.1"/>
                    <measurement group_id="O3" value="0.22" spread="49.9"/>
                    <measurement group_id="O4" value="0.23" spread="53.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vatreptacog Alfa Clot Activity: Terminal Half-life (t1/2)</title>
        <time_frame>during 1-2 days after drug administration</time_frame>
        <population>PK analysis set included all the subjects not violating the protocol in a manner that was judged to affect PK endpoint evaluation. One (1) subject did not contribute to data.</population>
        <group_list>
          <group group_id="O1">
            <title>Vatreptacog Alfa 5 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 5 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O2">
            <title>Vatreptacog Alfa 10 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 10 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O3">
            <title>Vatreptacog Alfa 20 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 20 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O4">
            <title>Vatreptacog Alfa 30 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 30 mcg/kg bodyweight was administered intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Vatreptacog Alfa Clot Activity: Terminal Half-life (t1/2)</title>
          <population>PK analysis set included all the subjects not violating the protocol in a manner that was judged to affect PK endpoint evaluation. One (1) subject did not contribute to data.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.51" spread="59.0"/>
                    <measurement group_id="O2" value="4.90" spread="32.1"/>
                    <measurement group_id="O3" value="3.14" spread="49.9"/>
                    <measurement group_id="O4" value="3.07" spread="53.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vatreptacog Alfa Clot Activity- Total Clearance (CL)</title>
        <time_frame>during 1-2 days after drug administration</time_frame>
        <population>PK analysis set included all the subjects not violating the protocol in a manner that was judged to affect PK endpoint evaluation. Two (2) subjects did not contribute to data.</population>
        <group_list>
          <group group_id="O1">
            <title>Vatreptacog Alfa 5 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 5 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O2">
            <title>Vatreptacog Alfa 10 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 10 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O3">
            <title>Vatreptacog Alfa 20 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 20 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O4">
            <title>Vatreptacog Alfa 30 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 30 mcg/kg bodyweight was administered intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Vatreptacog Alfa Clot Activity- Total Clearance (CL)</title>
          <population>PK analysis set included all the subjects not violating the protocol in a manner that was judged to affect PK endpoint evaluation. Two (2) subjects did not contribute to data.</population>
          <units>mL/h/kg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.14" spread="16.5"/>
                    <measurement group_id="O2" value="129.56" spread="6.3"/>
                    <measurement group_id="O3" value="110.82" spread="6.6"/>
                    <measurement group_id="O4" value="108.30" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vatreptacog Alfa Clot Activity- Apparent Volume of Distribution at Steady State (Vss)</title>
        <time_frame>during 1-2 days after drug administration</time_frame>
        <population>PK analysis set included all the subjects not violating the protocol in a manner that was judged to affect PK endpoint evaluation. Two (2) subject did not contribute to PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Vatreptacog Alfa 5 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 5 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O2">
            <title>Vatreptacog Alfa 10 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 10 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O3">
            <title>Vatreptacog Alfa 20 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 20 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O4">
            <title>Vatreptacog Alfa 30 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 30 mcg/kg bodyweight was administered intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Vatreptacog Alfa Clot Activity- Apparent Volume of Distribution at Steady State (Vss)</title>
          <population>PK analysis set included all the subjects not violating the protocol in a manner that was judged to affect PK endpoint evaluation. Two (2) subject did not contribute to PK evaluation.</population>
          <units>mL/kg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164.23" spread="55.0"/>
                    <measurement group_id="O2" value="131.72" spread="15.4"/>
                    <measurement group_id="O3" value="83.23" spread="18.5"/>
                    <measurement group_id="O4" value="79.67" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vatreptacog Alfa Clot Activity- Initial Volume of Distribution (VD)</title>
        <time_frame>during 1-2 days after drug administration</time_frame>
        <population>PK analysis set included all the subjects not violating the protocol in a manner that was judged to affect PK endpoint evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Vatreptacog Alfa 5 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 5 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O2">
            <title>Vatreptacog Alfa 10 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 10 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O3">
            <title>Vatreptacog Alfa 20 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 20 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O4">
            <title>Vatreptacog Alfa 30 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 30 mcg/kg bodyweight was administered intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Vatreptacog Alfa Clot Activity- Initial Volume of Distribution (VD)</title>
          <population>PK analysis set included all the subjects not violating the protocol in a manner that was judged to affect PK endpoint evaluation.</population>
          <units>mL/kg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.15" spread="10.5"/>
                    <measurement group_id="O2" value="49.31" spread="15.2"/>
                    <measurement group_id="O3" value="48.41" spread="5.8"/>
                    <measurement group_id="O4" value="47.67" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vatreptacog Alfa Clot Activity- Mean Residence Time (MRT)</title>
        <description>Mean residence time of the unchanged drug in the systemic circulation</description>
        <time_frame>during 1-2 days after drug administration</time_frame>
        <population>PK analysis set included all the subjects not violating the protocol in a manner that was judged to affect PK endpoint evaluation. One (1) subject did not contribute to PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Vatreptacog Alfa 5 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 5 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O2">
            <title>Vatreptacog Alfa 10 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 10 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O3">
            <title>Vatreptacog Alfa 20 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 20 mcg/kg bodyweight was administered intravenously</description>
          </group>
          <group group_id="O4">
            <title>Vatreptacog Alfa 30 mcg/kg</title>
            <description>A single dose of Vatreptacog alfa 30 mcg/kg bodyweight was administered intravenously</description>
          </group>
        </group_list>
        <measure>
          <title>Vatreptacog Alfa Clot Activity- Mean Residence Time (MRT)</title>
          <description>Mean residence time of the unchanged drug in the systemic circulation</description>
          <population>PK analysis set included all the subjects not violating the protocol in a manner that was judged to affect PK endpoint evaluation. One (1) subject did not contribute to PK evaluation.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" spread="73.0"/>
                    <measurement group_id="O2" value="1.02" spread="14.5"/>
                    <measurement group_id="O3" value="0.75" spread="20.5"/>
                    <measurement group_id="O4" value="0.74" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>After dosing adverse events were collected for approximately 11-13 weeks.</time_frame>
      <desc>Safety analysis set includes all subjects who received at least one dose of the investigational product or its comparator.</desc>
      <group_list>
        <group group_id="E1">
          <title>Vatreptacog Alfa 5 mcg/kg</title>
          <description>A single dose of Vatreptacog alfa 5 mcg/kg bodyweight was administered intravenously</description>
        </group>
        <group group_id="E2">
          <title>Vatreptacog Alfa 10 mcg/kg</title>
          <description>A single dose of Vatreptacog alfa 10 mcg/kg bodyweight was administered intravenously</description>
        </group>
        <group group_id="E3">
          <title>Vatreptacog Alfa 20 mcg/kg</title>
          <description>A single dose of Vatreptacog alfa 20 mcg/kg bodyweight was administered intravenously</description>
        </group>
        <group group_id="E4">
          <title>Vatreptacog Alfa 30 mcg/kg</title>
          <description>A single dose of Vatreptacog alfa 30 mcg/kg bodyweight was administered intravenously</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>A single dose of placebo was administered intravenously</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Novo Nordisk reserves the right to defer data release until specified milestones, e.g. availability of a clinical trial report. Novo Nordisk reserves the right to postpone publication and/or communication for less than 60 days to protect intellectual property. Novo Nordisk reserves the right to prior review of site-specific publications and to ask for deferment of publication of individual site results until after the primary manuscript is accepted for publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Public Access to Clinical Trials</name_or_title>
      <organization>Novo Nordisk A/S</organization>
      <email>clinicaltrials@novonordisk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

